Back to today’s briefing

Story perspectives

Breakthrough Non-Hormonal Male Contraceptive Passes Safety Trial

8/1/2025

50 7

Summary

Story summary

YCT-529, an innovative non-hormonal male contraceptive, has successfully passed its initial human safety trial with 16 participants, demonstrating excellent tolerability and no serious side effects. By targeting the retinoic acid receptor–? in the testes, it sidesteps hormonal effects. With larger trials on the horizon, this breakthrough could revolutionize male contraception.

1 of 1

Story summary

YCT-529, an innovative non-hormonal male contraceptive, has successfully passed its initial human safety trial with 16 participants, demonstrating excellent tolerability and no serious side effects. By targeting the retinoic acid receptor–? in the testes, it sidesteps hormonal effects. With larger trials on the horizon, this breakthrough could revolutionize male contraception.